Healthtech Startup Genefitletics Raises Undisclosed Amount In Pre-Seed Funding
The company plans to use the funds to develop oral microbiome and human genes expression tests, as well as launch its own brand of precision biotics.
Genefitletics is a Direct-to-Consumer Microbiome Company that pioneers application of microbial technology to save human life. A group of Angels has raised an amount undisclosed at a pre-money valuation INR 7.5 crore. The funds will be used to develop an oral microbiome test and a human gene expression test, as well as to launch the company's own brand of precision biotics. The funds will be used to develop machine learning models of human biology to help decode the cause of poor health.
"The healthcare system is focused on suppressing immune system, rather than finding the cause of disease. In turn, more people are diagnosed with diseases and side effects. They also receive more prescriptions for drugs. Researchers have discovered that the microbes, which we had been trying to eliminate for more than 200 years because they were harmful to us, are the key to our future health and longevity. We founded Genefitletics with this knowledge of the invisible army microbes that live on and inside us to help protect, restore and save our health.
The company works on breakthrough discoveries in microbiology to bridge the gap between science and human health. According to an official company statement, the platform of the company, PROTEBA, combines microbial sequences, artificial intelligence, and scientific research in order to create a pipeline of consumer healthcare solutions, precision diagnostics, and precision biotherapeutics that promote better health and longer life.